메뉴 건너뛰기




Volumn 7, Issue 1, 2014, Pages 113-124

Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions

Author keywords

Anticoagulants; Atrial fibrillation; Stents

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; APIXABAN; CLOPIDOGREL; DABIGATRAN; DABIGATRAN ETEXILATE; ENOXAPARIN; EVEROLIMUS; HEPARIN; PRASUGREL; PROTON PUMP INHIBITOR; RIVAROXABAN; TICAGRELOR; WARFARIN; ZOTAROLIMUS;

EID: 84900435999     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.113.001150     Document Type: Article
Times cited : (67)

References (121)
  • 1
    • 0034778819 scopus 로고    scopus 로고
    • Population prevalence, incidence, and predictors of atrial fibrillation in the renfrew/paisley study
    • Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart. 2001;86:516-521.
    • (2001) Heart , vol.86 , pp. 516-521
    • Stewart, S.1    Hart, C.L.2    Hole, D.J.3    McMurray, J.J.4
  • 2
    • 0035832261 scopus 로고    scopus 로고
    • Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The anticoagulation and risk factors in atrial fibrillation (atria) study
    • Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370-2375.
    • (2001) JAMA , vol.285 , pp. 2370-2375
    • Go, A.S.1    Hylek, E.M.2    Phillips, K.A.3    Chang, Y.4    Henault, L.E.5    Selby, J.V.6    Singer, D.E.7
  • 3
    • 33747052359 scopus 로고    scopus 로고
    • Secular trends in incidence of atrial fibrillation in olmsted county, minnesota, 1980 to 2000, and implications on the projections for future prevalence
    • Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang TS. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114:119-125.
    • (2006) Circulation , vol.114 , pp. 119-125
    • Miyasaka, Y.1    Barnes, M.E.2    Gersh, B.J.3    Cha, S.S.4    Bailey, K.R.5    Abhayaratna, W.P.6    Seward, J.B.7    Tsang, T.S.8
  • 5
    • 0025779484 scopus 로고
    • Atrial fibrillation as an independent risk factor for stroke: The framingham study
    • Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-988.
    • (1991) Stroke , vol.22 , pp. 983-988
    • Wolf, P.A.1    Abbott, R.D.2    Kannel, W.B.3
  • 9
    • 71749087343 scopus 로고    scopus 로고
    • Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin k antagonists in denmark: A retrospective analysis of nationwide registry data
    • Sorensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Andersson C, Jorgensen C, Madsen JK, Hansen PR, Kober L, Torp-Pedersen C, Gislason GH. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009;374:1967-1974.
    • (2009) Lancet , vol.374 , pp. 1967-1974
    • Sorensen, R.1    Hansen, M.L.2    Abildstrom, S.Z.3    Hvelplund, A.4    Andersson, C.5    Jorgensen, C.6    Madsen, J.K.7    Hansen, P.R.8    Kober, L.9    Torp-Pedersen, C.10    Gislason, G.H.11
  • 10
    • 80052999262 scopus 로고    scopus 로고
    • Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography
    • Kralev S, Schneider K, Lang S, Suselbeck T, Borggrefe M. Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography. PLoS One. 2011;6:e24964.
    • (2011) PLoS One , vol.6
    • Kralev, S.1    Schneider, K.2    Lang, S.3    Suselbeck, T.4    Borggrefe, M.5
  • 12
    • 84884165644 scopus 로고    scopus 로고
    • Congestive heart failure and decongestion ability of two different treatments: Continuous renal replacement and diuretic therapy: Experience of a cardiac step down unit
    • Giglioli C, Spini V, Landi D, Chiostri M, Romano SM, Calabretta R, Gensini GF, Cecchi E. Congestive heart failure and decongestion ability of two different treatments: continuous renal replacement and diuretic therapy: experience of a cardiac step down unit. Acta Cardiol. 2013;68:355-364.
    • (2013) Acta Cardiol , vol.68 , pp. 355-364
    • Giglioli, C.1    Spini, V.2    Landi, D.3    Chiostri, M.4    Romano, S.M.5    Calabretta, R.6    Gensini, G.F.7    Cecchi, E.8
  • 13
    • 84862763541 scopus 로고    scopus 로고
    • Effect of new versus known versus no atrial fibrillation on 30-day and 10-year mortality in patients with acute coronary syndrome
    • Poci D, Hartford M, Karlsson T, Edvardsson N, Caidahl K. Effect of new versus known versus no atrial fibrillation on 30-day and 10-year mortality in patients with acute coronary syndrome. Am J Cardiol. 2012;110:217-221.
    • (2012) Am J Cardiol , vol.110 , pp. 217-221
    • Poci, D.1    Hartford, M.2    Karlsson, T.3    Edvardsson, N.4    Caidahl, K.5
  • 17
    • 34347394385 scopus 로고    scopus 로고
    • Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation
    • Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-867.
    • (2007) Ann Intern Med , vol.146 , pp. 857-867
    • Hart, R.G.1    Pearce, L.A.2    Aguilar, M.I.3
  • 18
    • 33744945247 scopus 로고    scopus 로고
    • Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (active w): A randomised controlled trial
    • ACTIVE Writing Group of the ACTIVE Investigators
    • ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Pfeffer M, Hohnloser S, Yusuf S. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367:1903-1912.
    • (2006) Lancet , vol.367 , pp. 1903-1912
    • Connolly, S.1    Pogue, J.2    Hart, R.3    Pfeffer, M.4    Hohnloser, S.5    Chrolavicius, S.6    Pfeffer, M.7    Hohnloser, S.8    Yusuf, S.9
  • 19
    • 84876862702 scopus 로고    scopus 로고
    • Risk of stroke or systemic embolism in atrial fibrillation patients treated with warfarin: A systematic review and meta-analysis
    • Albertsen IE, Rasmussen LH, Overvad TF, Graungaard T, Larsen TB, Lip GY. Risk of stroke or systemic embolism in atrial fibrillation patients treated with warfarin: a systematic review and meta-analysis. Stroke. 2013;44:1329-1336.
    • (2013) Stroke , vol.44 , pp. 1329-1336
    • Albertsen, I.E.1    Rasmussen, L.H.2    Overvad, T.F.3    Graungaard, T.4    Larsen, T.B.5    Lip, G.Y.6
  • 20
    • 0033593072 scopus 로고    scopus 로고
    • Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: The anticoagulation and risk factors in atrial fibrillation (atria) study
    • Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med. 1999;131:927-934.
    • (1999) Ann Intern Med , vol.131 , pp. 927-934
    • Go, A.S.1    Hylek, E.M.2    Borowsky, L.H.3    Phillips, K.A.4    Selby, J.V.5    Singer, D.E.6
  • 21
    • 80055083430 scopus 로고    scopus 로고
    • Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin k antagonists are unsuitable
    • ACTIVE (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) Steering Committee and Investigators
    • Connolly SJ, Eikelboom JW, Ng J, Hirsh J, Yusuf S, Pogue J, de Caterina R, Hohnloser S, Hart RG; ACTIVE (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) Steering Committee and Investigators. Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. Ann Intern Med. 2011;155:579-586.
    • (2011) Ann Intern Med , vol.155 , pp. 579-586
    • Connolly, S.J.1    Eikelboom, J.W.2    Ng, J.3    Hirsh, J.4    Yusuf, S.5    Pogue, J.6    De Caterina, R.7    Hohnloser, S.8    Hart, R.G.9
  • 22
    • 84868523625 scopus 로고    scopus 로고
    • 2012 Focused update of the esc guidelines for the management of atrial fibrillation: An update of the 2010 esc guidelines for the management of atrial fibrillation. Developed with the special contribution of the european heart rhythm association
    • ESC Committee for Practice Guidelines (CPG
    • Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719-2747.
    • (2012) Eur Heart J , vol.33 , pp. 2719-2747
    • Camm, A.J.1    Lip, G.Y.2    De Caterina, R.3    Savelieva, I.4    Atar, D.5    Hohnloser, S.H.6    Hindricks, G.7    Kirchhof, P.8
  • 24
    • 84869236631 scopus 로고    scopus 로고
    • Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: A systematic review and meta-analysis of the literature
    • Dentali F, Riva N, Crowther M, Turpie AG, Lip GY, Ageno W. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation. 2012;126:2381-2391.
    • (2012) Circulation , vol.126 , pp. 2381-2391
    • Dentali, F.1    Riva, N.2    Crowther, M.3    Turpie, A.G.4    Lip, G.Y.5    Ageno, W.6
  • 25
    • 84881477376 scopus 로고    scopus 로고
    • Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: A meta-analysis of 50,578 patients
    • Capodanno D, Capranzano P, Giacchi G, Calvi V, Tamburino C. Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: a meta-analysis of 50,578 patients. Int J Cardiol. 2013;167:1237-1241.
    • (2013) Int J Cardiol , vol.167 , pp. 1237-1241
    • Capodanno, D.1    Capranzano, P.2    Giacchi, G.3    Calvi, V.4    Tamburino, C.5
  • 27
    • 84856158305 scopus 로고    scopus 로고
    • Esc committee for practice guidelines. Esc guidelines for the management of acute coronary syndromes in patients presenting without persistent st-segment elevation: The task force for the management of acute coronary syndromes (acs) in patients presenting without persistent st-segment elevation of the european society of cardiology (esc
    • Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, Wijns W, Zahger D; ESC Committee for Practice Guidelines. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:2999-3054.
    • (2011) Eur Heart J , vol.32 , pp. 2999-3054
    • Hamm, C.W.1    Bassand, J.P.2    Agewall, S.3    Bax, J.4    Boersma, E.5    Bueno, H.6    Caso, P.7    Dudek, D.8    Gielen, S.9    Huber, K.10    Ohman, M.11    Petrie, M.C.12    Sonntag, F.13    Uva, M.S.14    Storey, R.F.15    Wijns, W.16    Zahger, D.17
  • 30
    • 0035899289 scopus 로고    scopus 로고
    • Clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without st-segment elevation
    • Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
    • (2001) N Engl J Med , vol.345 , pp. 494-502
    • Yusuf, S.1    Zhao, F.2    Mehta, S.R.3    Chrolavicius, S.4    Tognoni, G.5    Fox, K.K.6
  • 31
    • 0037145863 scopus 로고    scopus 로고
    • Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial
    • Steinhubl SR, Berger PB, Mann JT III, Fry ET, DeLago A, Wilmer C, Topol EJ; CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-2420.
    • (2002) JAMA , vol.288 , pp. 2411-2420
    • Steinhubl, S.R.1    Berger, P.B.2    Mann III, J.T.3    Fry, E.T.4    DeLago, A.5    Wilmer, C.6    Topol, E.J.7    Credo, I.8
  • 33
    • 84880616993 scopus 로고    scopus 로고
    • Antiplatelet therapy: New pharmacological agents and changing paradigms
    • Capodanno D, Ferreiro JL, Angiolillo DJ. Antiplatelet therapy: new pharmacological agents and changing paradigms. J Thromb Haemost. 2013;11(suppl 1):316-329.
    • (2013) J Thromb Haemost , vol.11 , Issue.SUPPL. 1 , pp. 316-329
    • Capodanno, D.1    Ferreiro, J.L.2    Angiolillo, D.J.3
  • 35
    • 80052741598 scopus 로고    scopus 로고
    • Efficacy and safety of intensive antiplatelet therapy with prasugrel from triton-timi 38 in a core clinical cohort defined by worldwide regulatory agencies
    • Wiviott SD, Desai N, Murphy SA, Musumeci G, Ragosta M, Antman EM, Braunwald E. Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies. Am J Cardiol. 2011;108:905-911.
    • (2011) Am J Cardiol , vol.108 , pp. 905-911
    • Wiviott, S.D.1    Desai, N.2    Murphy, S.A.3    Musumeci, G.4    Ragosta, M.5    Antman, E.M.6    Braunwald, E.7
  • 39
    • 17644388105 scopus 로고    scopus 로고
    • Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction
    • Buresly K, Eisenberg MJ, Zhang X, Pilote L. Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. Arch Intern Med. 2005;165:784-789.
    • (2005) Arch Intern Med , vol.165 , pp. 784-789
    • Buresly, K.1    Eisenberg, M.J.2    Zhang, X.3    Pilote, L.4
  • 40
    • 71749087343 scopus 로고    scopus 로고
    • Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin k antagonists in denmark: A retrospective analysis of nationwide registry data
    • Sorensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Andersson C, Jorgensen C, Madsen JK, Hansen PR, Kober L, Torp-Pedersen C, Gislason GH. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009;374:1967-1974.
    • (2009) Lancet , vol.374 , pp. 1967-1974
    • Sorensen, R.1    Hansen, M.L.2    Abildstrom, S.Z.3    Hvelplund, A.4    Andersson, C.5    Jorgensen, C.6    Madsen, J.K.7    Hansen, P.R.8    Kober, L.9    Torp-Pedersen, C.10    Gislason, G.H.11
  • 41
    • 84865863475 scopus 로고    scopus 로고
    • Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: A nationwide cohort study
    • Lamberts M, Olesen JB, Ruwald MH, Hansen CM, Karasoy D, Kristensen SL, Kober L, Torp-Pedersen C, Gislason GH, Hansen ML. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation. 2012;126:1185-1193.
    • (2012) Circulation , vol.126 , pp. 1185-1193
    • Lamberts, M.1    Olesen, J.B.2    Ruwald, M.H.3    Hansen, C.M.4    Karasoy, D.5    Kristensen, S.L.6    Kober, L.7    Torp-Pedersen, C.8    Gislason, G.H.9    Hansen, M.L.10
  • 43
    • 84884479019 scopus 로고    scopus 로고
    • Ibaraki cardiovascular assessment study (icas) registry. Triple antithrombotic therapy is the independent predictor for the occurrence of major bleeding complications: Analysis of percent time in therapeutic range
    • Naruse Y, Sato A, Hoshi T, Takeyasu N, Kakefuda Y, Ishibashi M, Misaki M, Abe D, Aonuma K; Ibaraki Cardiovascular Assessment Study (ICAS) Registry. Triple antithrombotic therapy is the independent predictor for the occurrence of major bleeding complications: analysis of percent time in therapeutic range. Circ Cardiovasc Interv. 2013;6:444-451.
    • (2013) Circ Cardiovasc Interv , vol.6 , pp. 444-451
    • Naruse, Y.1    Sato, A.2    Hoshi, T.3    Takeyasu, N.4    Kakefuda, Y.5    Ishibashi, M.6    Misaki, M.7    Abe, D.8    Aonuma, K.9
  • 44
    • 79952816422 scopus 로고    scopus 로고
    • Meta-analysis of the combination of warfarin and dual antiplatelet therapy after coronary stenting in patients with indications for chronic oral anticoagulation
    • Gao F, Zhou YJ, Wang ZJ, Yang SW, Nie B, Liu XL, Jia de A, Yan ZX. Meta-analysis of the combination of warfarin and dual antiplatelet therapy after coronary stenting in patients with indications for chronic oral anticoagulation. Int J Cardiol. 2011;148:96-101.
    • (2011) Int J Cardiol , vol.148 , pp. 96-101
    • Gao, F.1    Zhou, Y.J.2    Wang, Z.J.3    Yang, S.W.4    Nie, B.5    Liu, X.L.6    Jia De, A.7    Yan, Z.X.8
  • 45
    • 79551592248 scopus 로고    scopus 로고
    • Triple therapy" rather than "triple threat": A meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment
    • Zhao HJ, Zheng ZT, Wang ZH, Li SH, Zhang Y, Zhong M, Zhang W. "Triple therapy" rather than "triple threat": a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment. Chest. 2011;139:260-270.
    • (2011) Chest , vol.139 , pp. 260-270
    • Zhao, H.J.1    Zheng, Z.T.2    Wang, Z.H.3    Li, S.H.4    Zhang, Y.5    Zhong, M.6    Zhang, W.7
  • 46
    • 84855409970 scopus 로고    scopus 로고
    • The risk of bleeding of triple therapy with vitamin k-antagonists, aspirin and clopidogrel after coronary stent implantation: Facts and questions
    • Rubboli A. The risk of bleeding of triple therapy with vitamin K-antagonists, aspirin and clopidogrel after coronary stent implantation: facts and questions. J Geriatr Cardiol. 2011;8:207-214.
    • (2011) J Geriatr Cardiol , vol.8 , pp. 207-214
    • Rubboli, A.1
  • 48
    • 74249099911 scopus 로고    scopus 로고
    • European society of cardiology working group on thrombosis. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting
    • Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen KJ, Cuisset T, Kirchhof P, Marin F; European Society of Cardiology Working Group on Thrombosis. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Thromb Haemost. 2010;103:13-28.
    • (2010) Thromb Haemost , vol.103 , pp. 13-28
    • Lip, G.Y.1    Huber, K.2    Andreotti, F.3    Arnesen, H.4    Airaksinen, K.J.5    Cuisset, T.6    Kirchhof, P.7    Marin, F.8
  • 53
    • 33748680917 scopus 로고    scopus 로고
    • Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: Design and rationale for the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel thrombolysis in myocardial infarction 38 (triton-timi 38
    • TRITON-TIMI 38 Investigators
    • Wiviott SD, Antman EM, Gibson CM, Montalescot G, Riesmeyer J, Weerakkody G, Winters KJ, Warmke JW, McCabe CH, Braunwald E; TRITON-TIMI 38 Investigators. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J. 2006;152:627-635.
    • (2006) Am Heart J , vol.152 , pp. 627-635
    • Wiviott, S.D.1    Antman, E.M.2    Gibson, C.M.3    Montalescot, G.4    Riesmeyer, J.5    Weerakkody, G.6    Winters, K.J.7    Warmke, J.W.8    McCabe, C.H.9    Braunwald, E.10
  • 55
    • 84877762403 scopus 로고    scopus 로고
    • Triple therapy with aspirin, prasugrel, and vitamin k antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation
    • Sarafoff N, Martischnig A, Wealer J, Mayer K, Mehilli J, Sibbing D, Kastrati A. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. J Am Coll Cardiol. 2013;61:2060-2066.
    • (2013) J Am Coll Cardiol , vol.61 , pp. 2060-2066
    • Sarafoff, N.1    Martischnig, A.2    Wealer, J.3    Mayer, K.4    Mehilli, J.5    Sibbing, D.6    Kastrati, A.7
  • 57
    • 84900459162 scopus 로고    scopus 로고
    • Brilinta (Ticagrelor). Highlights of prescribin information. Accessed November 17, 2013
    • Brilinta (Ticagrelor). Highlights of prescribin information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/022433s008lbl.pdf. Accessed November 17, 2013.
  • 67
    • 0035854054 scopus 로고    scopus 로고
    • Validation of clinical classification schemes for predicting stroke: Results from the national registry of atrial fibrillation
    • Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864-2870.
    • (2001) JAMA , vol.285 , pp. 2864-2870
    • Gage, B.F.1    Waterman, A.D.2    Shannon, W.3    Boechler, M.4    Rich, M.W.5    Radford, M.J.6
  • 68
    • 78349301230 scopus 로고    scopus 로고
    • Antithrombotic therapy in the elderly
    • Capodanno D, Angiolillo DJ. Antithrombotic therapy in the elderly. J Am Coll Cardiol. 2010;56:1683-1692.
    • (2010) J Am Coll Cardiol , vol.56 , pp. 1683-1692
    • Capodanno, D.1    Angiolillo, D.J.2
  • 72
    • 84888135235 scopus 로고    scopus 로고
    • Afcas (management of patients with atrial fibrillation undergoing coronary artery stenting study group). The management of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: In-hospital-data from the atrial fibrillation undergoing coronary artery stenting study
    • Schlitt A, Rubboli A, Lip GY, Lahtela H, Valencia J, Karjalainen PP, Weber M, Laine M, Kirchhof P, Niemela M, Vikman S, Buerke M, Airaksinen KE; AFCAS (Management of patients with Atrial Fibrillation undergoing Coronary Artery Stenting Study Group). The management of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: in-hospital-data from the atrial fibrillation undergoing coronary artery stenting study. Catheter Cardiovasc Interv. 2013;82:E864-E870.
    • (2013) Catheter Cardiovasc Interv , vol.82
    • Schlitt, A.1    Rubboli, A.2    Lip, G.Y.3    Lahtela, H.4    Valencia, J.5    Karjalainen, P.P.6    Weber, M.7    Laine, M.8    Kirchhof, P.9    Niemela, M.10    Vikman, S.11    Buerke, M.12    Airaksinen, K.E.13
  • 73
    • 57149140461 scopus 로고    scopus 로고
    • Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range
    • ACTIVE W Investigators
    • Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, Healey JS, Yusuf S; ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008;118:2029-2037.
    • (2008) Circulation , vol.118 , pp. 2029-2037
    • Connolly, S.J.1    Pogue, J.2    Eikelboom, J.3    Flaker, G.4    Commerford, P.5    Franzosi, M.G.6    Healey, J.S.7    Yusuf, S.8
  • 74
    • 57149103475 scopus 로고    scopus 로고
    • Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: A systematic review and meta-analysis of randomized trials
    • Jolly SS, Amlani S, Hamon M, Yusuf S, Mehta SR. Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: a systematic review and meta-analysis of randomized trials. Am Heart J. 2009;157:132-140.
    • (2009) Am Heart J , vol.157 , pp. 132-140
    • Jolly, S.S.1    Amlani, S.2    Hamon, M.3    Yusuf, S.4    Mehta, S.R.5
  • 76
    • 33744779419 scopus 로고    scopus 로고
    • Percutaneous left and right heart catheterization in fully anticoagulated patients utilizing the radial artery and forearm vein: A two-center experience
    • Lo TS, Buch AN, Hall IR, Hildick-Smith DJ, Nolan J. Percutaneous left and right heart catheterization in fully anticoagulated patients utilizing the radial artery and forearm vein: a two-center experience. J Interv Cardiol. 2006;19:258-263.
    • (2006) J Interv Cardiol , vol.19 , pp. 258-263
    • Lo, T.S.1    Buch, A.N.2    Hall, I.R.3    Hildick-Smith, D.J.4    Nolan, J.5
  • 79
    • 84862128532 scopus 로고    scopus 로고
    • Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: A mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials
    • Bangalore S, Kumar S, Fusaro M, Amoroso N, Attubato MJ, Feit F, Bhatt DL, Slater J. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation. 2012;125:2873-2891.
    • (2012) Circulation , vol.125 , pp. 2873-2891
    • Bangalore, S.1    Kumar, S.2    Fusaro, M.3    Amoroso, N.4    Attubato, M.J.5    Feit, F.6    Bhatt, D.L.7    Slater, J.8
  • 83
    • 84866604206 scopus 로고    scopus 로고
    • Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: Mixed treatment comparison analysis of 22,844 patient years of follow-up from randomised trials
    • Bangalore S, Kumar S, Fusaro M, Amoroso N, Kirtane AJ, Byrne RA, Williams DO, Slater J, Cutlip DE, Feit F. Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomised trials. BMJ. 2012;345:e5170.
    • (2012) BMJ , vol.345
    • Bangalore, S.1    Kumar, S.2    Fusaro, M.3    Amoroso, N.4    Kirtane, A.J.5    Byrne, R.A.6    Williams, D.O.7    Slater, J.8    Cutlip, D.E.9    Feit, F.10
  • 84
    • 84890924325 scopus 로고    scopus 로고
    • Management of antiplatelet therapy in patients with coronary artery disease requiring cardiac and noncardiac surgery
    • Capodanno D, Angiolillo DJ. Management of antiplatelet therapy in patients with coronary artery disease requiring cardiac and noncardiac surgery. Circulation. 2013;128:2785-2798.
    • (2013) Circulation , vol.128 , pp. 2785-2798
    • Capodanno, D.1    Angiolillo, D.J.2
  • 85
    • 84900446088 scopus 로고    scopus 로고
    • Abbott's XIENCE PRIME™ and XIENCE V® Drug Eluting Stents Receive Indication in Europe for Minimum Three-Month Duration of Dual Anti-Platelet Therapy. Accessed December 8, 2013
    • Abbott's XIENCE PRIME™ and XIENCE V® Drug Eluting Stents Receive Indication in Europe for Minimum Three-Month Duration of Dual Anti-Platelet Therapy. http://www.abbott.us/news-media/pressreleases/abbotts- xience-prime-and-xience-v-drug-eluting-stents-receiveindication- in-europe-for-minimum-th.htm. Accessed December 8, 2013.
  • 86
    • 84900421128 scopus 로고    scopus 로고
    • Medtronic Approved to Update Resolute Integrity Stent's 'CE' Mark Labeling on Dual Antiplatelet Therapy. Accessed December 8, 2013
    • Medtronic Approved to Update Resolute Integrity Stent's 'CE' Mark Labeling on Dual Antiplatelet Therapy. http://wwwp.medtronic.com/Newsroom/ NewsReleaseDetails.do?itemId=1361899837211&lang=en-US. Accessed December 8, 2013.
  • 87
    • 84888209343 scopus 로고    scopus 로고
    • Difficult decisions with dual antiplatelet therapy: Des, stemi, unplanned treatment interruption
    • may 14-17, 2012; paris, france.
    • Palmerini T. Difficult decisions with dual antiplatelet therapy: DES, STEMI, unplanned treatment interruption. Paper presented at: EuroPCR; May 14-17, 2012; Paris, France.
    • Paper Presented At: Europcr
    • Palmerini, T.1
  • 92
    • 84885441282 scopus 로고    scopus 로고
    • Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents
    • Hawn MT, Graham LA, Richman JS, Itani KM, Henderson WG, Maddox TM. Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents. JAMA. 2013;310:1462-1472.
    • (2013) JAMA , vol.310 , pp. 1462-1472
    • Hawn, M.T.1    Graham, L.A.2    Richman, J.S.3    Itani, K.M.4    Henderson, W.G.5    Maddox, T.M.6
  • 93
    • 77956167248 scopus 로고    scopus 로고
    • Coronary stents: Looking forward
    • Garg S, Serruys PW. Coronary stents: looking forward. J Am Coll Cardiol. 2010;56(10 suppl):S43-S78.
    • (2010) J Am Coll Cardiol , vol.56 , Issue.10 SUPPL.
    • Garg, S.1    Serruys, P.W.2
  • 94
    • 84861733232 scopus 로고    scopus 로고
    • Afcas (management of patients with atrial fibrillation undergoing coronary artery stenting) study group. Heparin bridging vs. Uninterrupted oral anticoagulation in patients with atrial fibrillation undergoing coronary artery stenting. Results from the afcas registry
    • Lahtela H, Rubboli A, Schlitt A, Karjalainen PP, Niemela M, Vikman S, Puurunen M, Weber M, Valencia J, Biancari F, Lip GY, Airaksinen KE; AFCAS (Management of patients with Atrial Fibrillation undergoing Coronary Artery Stenting) study group. Heparin bridging vs. uninterrupted oral anticoagulation in patients with Atrial Fibrillation undergoing Coronary Artery Stenting. Results from the AFCAS registry. Circ J. 2012;76:1363-1368.
    • (2012) Circ J , vol.76 , pp. 1363-1368
    • Lahtela, H.1    Rubboli, A.2    Schlitt, A.3    Karjalainen, P.P.4    Niemela, M.5    Vikman, S.6    Puurunen, M.7    Weber, M.8    Valencia, J.9    Biancari, F.10    Lip, G.Y.11    Airaksinen, K.E.12
  • 96
    • 67650517543 scopus 로고    scopus 로고
    • Adding intravenous unfractionated heparin to standard enoxaparin causes excessive anticoagulation not detected by activated clotting time: Results of the stack-on to enoxaparin (stackenox) study
    • Drouet L, Bal dit Sollier C, Martin J. Adding intravenous unfractionated heparin to standard enoxaparin causes excessive anticoagulation not detected by activated clotting time: results of the STACK-on to ENOXaparin (STACKENOX) study. Am Heart J. 2009;158:177-184.
    • (2009) Am Heart J , vol.158 , pp. 177-184
    • Drouet, L.1    Bal Dit Sollier, C.2    Martin, J.3
  • 98
    • 84868657039 scopus 로고    scopus 로고
    • Bivalirudin versus heparin plus a glycoprotein iib/iiia inhibitor in patients with non-st-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: Pooled analysis from the acuity and isar-react 4 trials
    • Ndrepepa G, Neumann FJ, Deliargyris EN, Mehran R, Mehilli J, Ferenc M, Schulz S, Schomig A, Kastrati A, Stone GW. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials. Circ Cardiovasc Interv. 2012;5:705-712.
    • (2012) Circ Cardiovasc Interv , vol.5 , pp. 705-712
    • Ndrepepa, G.1    Neumann, F.J.2    Deliargyris, E.N.3    Mehran, R.4    Mehilli, J.5    Ferenc, M.6    Schulz, S.7    Schomig, A.8    Kastrati, A.9    Stone, G.W.10
  • 99
    • 79959696572 scopus 로고    scopus 로고
    • Heparin plus a glycoprotein iib/iiia inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (horizons-ami): Final 3-year results from a multicentre, randomised controlled trial
    • HORIZONS-AMI Trial Investigators
    • Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Fahy M, Parise H, Mehran R; HORIZONS-AMI Trial Investigators. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet. 2011;377:2193-2204.
    • (2011) Lancet , vol.377 , pp. 2193-2204
    • Stone, G.W.1    Witzenbichler, B.2    Guagliumi, G.3    Peruga, J.Z.4    Brodie, B.R.5    Dudek, D.6    Kornowski, R.7    Hartmann, F.8    Gersh, B.J.9    Pocock, S.J.10    Dangas, G.11    Wong, S.C.12    Fahy, M.13    Parise, H.14    Mehran, R.15
  • 100
    • 84864400448 scopus 로고    scopus 로고
    • Meta-analysis comparing bivalirudin versus heparin monotherapy on ischemic and bleeding outcomes after percutaneous coronary intervention
    • Bertrand OF, Jolly SS, Rao SV, Patel T, Belle L, Bernat I, Parodi G, Costerousse O, Mann T. Meta-analysis comparing bivalirudin versus heparin monotherapy on ischemic and bleeding outcomes after percutaneous coronary intervention. Am J Cardiol. 2012;110:599-606.
    • (2012) Am J Cardiol , vol.110 , pp. 599-606
    • Bertrand, O.F.1    Jolly, S.S.2    Rao, S.V.3    Patel, T.4    Belle, L.5    Bernat, I.6    Parodi, G.7    Costerousse, O.8    Mann, T.9
  • 101
    • 84878755472 scopus 로고    scopus 로고
    • Current status and ongoing development of reversing agents for novel oral anticoagulants (noacs
    • Capodanno D, Giacchi G, Tamburino C. Current status and ongoing development of reversing agents for novel oral anticoagulants (NOACs). Recent Pat Cardiovasc Drug Discov. 2013;8:2-9.
    • (2013) Recent Pat Cardiovasc Drug Discov , vol.8 , pp. 2-9
    • Capodanno, D.1    Giacchi, G.2    Tamburino, C.3
  • 106
    • 78650739879 scopus 로고    scopus 로고
    • 2008 Expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and nsaid use: A report of the
    • ACCF/ACG/AHA. ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA American College of Cardiology Foundation Task Force on Expert Consensus Documents
    • Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, Furberg CD, Johnson DA, Kahi CJ, Laine L, Mahaffey KW, Quigley EM, Scheiman J, Sperling LS, Tomaselli GF; ACCF/ACG/AHA. ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation. 2010;122:2619-2633.
    • (2010) Circulation , vol.122 , pp. 2619-2633
    • Abraham, N.S.1    Hlatky, M.A.2    Antman, E.M.3    Bhatt, D.L.4    Bjorkman, D.J.5    Clark, C.B.6    Furberg, C.D.7    Johnson, D.A.8    Kahi, C.J.9    Laine, L.10    Mahaffey, K.W.11    Quigley, E.M.12    Scheiman, J.13    Sperling, L.S.14    Tomaselli, G.F.15
  • 107
    • 84875215590 scopus 로고    scopus 로고
    • Accessed December 6, 2013
    • Plavix Prescribing Information. http://products.sanofi.us/plavix/plavix. html. Accessed December 6, 2013.
    • Plavix Prescribing Information
  • 108
    • 69249206873 scopus 로고    scopus 로고
    • Antiplatelet therapy: Clopidogrel plus ppis - A dangerous combination?
    • Ferreiro JL, Angiolillo DJ. Antiplatelet therapy: Clopidogrel plus PPIs-a dangerous combination? Nat Rev Cardiol. 2009;6:392-394.
    • (2009) Nat Rev Cardiol , vol.6 , pp. 392-394
    • Ferreiro, J.L.1    Angiolillo, D.J.2
  • 110
    • 78650517232 scopus 로고    scopus 로고
    • Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: Randomized, placebo-controlled, crossover comparison studies
    • Angiolillo DJ, Gibson CM, Cheng S, Ollier C, Nicolas O, Bergougnan L, Perrin L, LaCreta FP, Hurbin F, Dubar M. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011;89:65-74.
    • (2011) Clin Pharmacol Ther , vol.89 , pp. 65-74
    • Angiolillo, D.J.1    Gibson, C.M.2    Cheng, S.3    Ollier, C.4    Nicolas, O.5    Bergougnan, L.6    Perrin, L.7    LaCreta, F.P.8    Hurbin, F.9    Dubar, M.10
  • 111
    • 84859138447 scopus 로고    scopus 로고
    • A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers
    • Frelinger AL III, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Brooks JK, Bhatt DL, Michelson AD. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol. 2012;59:1304-1311.
    • (2012) J Am Coll Cardiol , vol.59 , pp. 1304-1311
    • Frelinger III, A.L.1    Lee, R.D.2    Mulford, D.J.3    Wu, J.4    Nudurupati, S.5    Nigam, A.6    Brooks, J.K.7    Bhatt, D.L.8    Michelson, A.D.9
  • 115
    • 23644443663 scopus 로고    scopus 로고
    • Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: Meta-analysis with estimates of risk and benefit
    • Rothberg MB, Celestin C, Fiore LD, Lawler E, Cook JR. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med. 2005;143:241-250.
    • (2005) Ann Intern Med , vol.143 , pp. 241-250
    • Rothberg, M.B.1    Celestin, C.2    Fiore, L.D.3    Lawler, E.4    Cook, J.R.5
  • 116
    • 0041829444 scopus 로고    scopus 로고
    • Oral ximelagatran for secondary prophylaxis after myocardial infarction: The esteem randomised controlled trial
    • Wallentin L, Wilcox RG, Weaver WD, Emanuelsson H, Goodvin A, Nystrom P, Bylock A; ESTEEM Investigators. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet. 2003;362:789-797.
    • (2003) Lancet , vol.362 , pp. 789-797
    • Wallentin, L.1    Wilcox, R.G.2    Weaver, W.D.3    Emanuelsson, H.4    Goodvin, A.5    Nystrom, P.6    Bylock, A.7    Esteem, I.8
  • 117
    • 80052232522 scopus 로고    scopus 로고
    • Dabigatran vs. Placebo in patients with acute coronary syndromes on dual antiplatelet therapy: A randomized, double-blind, phase ii trial
    • RE-DEEM Investigators
    • Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A, Tijssen JG, Van De Werf F, Wallentin L; RE-DEEM Investigators. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011;32:2781-2789.
    • (2011) Eur Heart J , vol.32 , pp. 2781-2789
    • Oldgren, J.1    Budaj, A.2    Granger, C.B.3    Khder, Y.4    Roberts, J.5    Siegbahn, A.6    Tijssen, J.G.7    Van De Werf, F.8    Wallentin, L.9
  • 118
    • 80054733922 scopus 로고    scopus 로고
    • Ruby-1: A randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor xa inhibitor darexaban (ym150) following acute coronary syndrome
    • RUBY-1 Investigators
    • Steg PG, Mehta SR, Jukema JW, Lip GY, Gibson CM, Kovar F, Kala P, Garcia-Hernandez A, Renfurm RW, Granger CB; RUBY-1 Investigators. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J. 2011;32:2541-2554.
    • (2011) Eur Heart J , vol.32 , pp. 2541-2554
    • Steg, P.G.1    Mehta, S.R.2    Jukema, J.W.3    Lip, G.Y.4    Gibson, C.M.5    Kovar, F.6    Kala, P.7    Garcia-Hernandez, A.8    Renfurm, R.W.9    Granger, C.B.10


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.